Clinical Trials Logo

Clinical Trial Summary

The demand for addiction care for patients with addiction to analgesics increases with the number of prescription of analgesics grade 2; this is a public health problem There is no support for repositories to date in the context of addiction analgesics grade 2.

Risk factors of misuse as well as diagnostic tools were identified.


Clinical Trial Description

The demand for addiction care for patients with addiction to analgesics increases with the number of prescription of analgesics grade 2; this is a public health problem There is no support for repositories to date in the context of addiction analgesics grade 2.

Risk factors of misuse as well as diagnostic tools were identified. The objectives of our research are to determine the characteristics of the individuals suffering from an addiction to analgesics of level 2 followed in consultation of addictology in the hospital of Montpellier and Nimes and to describe the type of follow-up proposed to the patients in these two centers. It is a retrospective and descriptive study.

As part of this research, we will solicit all the patients followed in consultation of addictology or in hospitalization to the hospital of Montpellier or Nîmes for an addiction to the analgesics of grade 2 between the 1st of January 2014 and the 10th of July 2017 with requests of management for withdrawal or reduction of doses, opioid analgesics in the absence of pain or in chronic non-cancer pain, opioid analgesics to avoid withdrawal syndrome or hyperalgesia and consumptions chronic to dosages inadequate to the functional complaint evaluated by the rhumatology or algology services.

The data are collected in the medical file at the two participating institutions (Montpellier and Nîmes) and if necessary, patients not seen in consultation for more than 6 months will be recontacted. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT03297853
Study type Observational
Source University Hospital, Montpellier
Contact
Status Completed
Phase
Start date January 1, 2014
Completion date March 30, 2018